Form 4: Verrica Pharmaceuticals' Chief Medical Officer Sells Shares to Cover Tax Obligations

Gary Goldenberg, Chief Medical Officer of Verrica Pharmaceuticals, sold shares of common stock to cover statutory tax withholding obligations related to the settlement of restricted stock units.

Summary

• Gary Goldenberg, the Chief Medical Officer of Verrica Pharmaceuticals, sold shares of the company's common stock on July 22 and July 23, 2024.
• The sales were executed to cover statutory tax withholding obligations associated with the settlement of restricted stock units.
• On July 22, 2024, 18,421 shares were sold at a weighted average price of $7.06.
• On July 23, 2024, 86 shares were sold at $6.98.
• Following these transactions, Goldenberg directly owns 107,750 shares of Verrica Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sell to cover taxes) and doesn't inherently indicate positive or negative sentiment regarding the company's prospects.

Industry Context

Sales of shares to cover tax obligations are a common practice among company executives when restricted stock units vest. This is a standard part of executive compensation and equity management.

Comparison to Industry Standards

• Similar 'sell to cover' transactions are common among executives at publicly traded pharmaceutical companies like Amgen, Gilead Sciences, and Regeneron, especially upon the vesting of restricted stock units.
• These transactions are typically disclosed via Form 4 filings with the SEC, providing transparency into insider trading activities.

Stakeholder Impact

• The sale of shares by a company executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
• The transaction is part of the company's equity incentive plan, which is designed to align the interests of management with those of shareholders.

Key Dates